inTEST vs Mesa Laboratories
INTT and MLAB side by side, both in laboratory apparatus and analytical, optical, measuring, and controlling instruments. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INTT and MLAB compare
Mesa Laboratories is the larger company, worth 4.2 times as much as inTEST ($779M against $186M).
On earnings, inTEST is cheaper: it trades at 48.3× trailing earnings, against 121× for Mesa Laboratories.
inTEST grew revenue faster over the last twelve months (16.6% versus 2.5% for Mesa Laboratories).
inTEST keeps more of each dollar of sales as profit, with a net margin of 2.7% compared with 2.7% at Mesa Laboratories.
Mesa Laboratories pays a dividend yielding 0.46%; inTEST does not pay one.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INTT | MLAB |
|---|---|---|
| Size and price | ||
| Market cap | $186M | $779M |
| Share price | $14.49 | $139.21 |
| Change, 1 year | 77.4% | 70.1% |
| Change, 5 years | −8.1% | −55.4% |
| Beta (5Y) | 1.37 | 1.00 |
| Employees | 407 | 717 |
| StockData Score | ||
| Total score | 11 | 11 |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 4 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 48.3× (better) | 121× |
| P/S | 1.4× (better) | 3.1× |
| P/B | 1.7× (better) | 4.0× |
| EV/EBITDA | 15.4× (better) | 28.9× |
| P/FCF | – | 15.8× |
| PEG | – | 1.31 |
| FCF yield | −0.13% | 6.3% (better) |
| Fair value | $11.80 | $81.27 |
| Margin of safety | −22.8% (better) | −71.3% |
| Growth | ||
| Revenue growth (TTM) | 16.6% (better) | 2.5% |
| Revenue growth, 5Y average | 16.2% (better) | 13.2% |
| EPS growth, 5Y average | – | 13.6% |
| Profitability | ||
| Gross margin | 44.2% | 64.8% (better) |
| Operating margin | 3.3% | 10.4% (better) |
| Net margin | 2.7% (better) | 2.7% |
| FCF margin | −0.17% | 19.7% (better) |
| Return on equity | 3.5% | 3.6% (better) |
| Return on invested capital | 4.0% | 7.9% (better) |
| Financial health | ||
| Debt / equity | 0.05 | – |
| Net debt / EBITDA | −1.39 | – |
| Interest coverage | 13.3× (better) | 2.6× |
| Current ratio | 2.63 (better) | 1.90 |
| Altman Z-score | 4.62 (better) | 2.54 |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.46% |
| Payout ratio | – | 53.3% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Shareholder yield | 0.00% | 0.46% (better) |
| Ownership | ||
| Held by institutions | 67.3% | 89.9% |
| Held by insiders | 5.7% | 3.6% |
| Insider net buying, 12 months | −$57.8K (better) | −$216K |
| Short interest, % of float | 2.8% | 7.0% |
Go deeper
- INTT stock overview
- INTT income statement
- INTT valuation and score
- MLAB stock overview
- MLAB income statement
- MLAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.